Absci (ABSI) closed at $8.54 on Oct 19, 2026, up 3.5% on the day. The stock is down 11.5% over the past month, up 2.6% over three months, up 144.7% year to date and up 75.4% over the past year. It trades 29.2% below its 52-week high of $12.06 and 281.2% above its 52-week low of $2.24. The close sits below its 50-day moving average ($9.33) and above its 200-day moving average ($6.19).
NextPick tracks ABSI in its AI Drug Discovery basket alongside TEM, ABCL, RXRX, SDGR and CERT. As of Oct 19, 2026, the basket's money-flow score is -38 (outflow), and the basket is down 6.9% over five sessions. Over the past month ABSI ranks 4th of 6 basket members by price change.
Yes — the Oct 19, 2026 close of $8.54 is 38.1% above the 200-day average of $6.19.
ABSI closed 29.2% below its 52-week high of $12.06.
NextPick groups ABSI with TEM, ABCL, RXRX, SDGR and CERT in its AI Drug Discovery basket.
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
